The historical account of what originally drove Dr. Crohn to dedicate his life to medicine centers on this relationship:

The Origin of the Quest

Growing up in New York City as one of 12 children in an immigrant family, young Burrill Crohn watched his father, Theodore Crohn, suffer constantly from severe, agonizing indigestion and terrible digestion problems. At the time, medical science had very little understanding of chronic gastrointestinal disorders, and his father could find no lasting relief.

Deeply affected by his father's daily struggle, Burrill made a personal vow to study medicine specifically to understand and cure his father’s stomach ailments.

The Accidental Legacy

This filial devotion drove him to graduate from Columbia University's College of Physicians and Surgeons in 1907. He spent decades tracking down the root causes of abdominal pain and chronic inflammation, eventually co-publishing the landmark 1932 paper at Mount Sinai Hospital that defined "regional ileitis"—the condition the medical world chose to permanently name Crohn's disease.

The Generational Twist

While Dr. Crohn went into medicine to save his father, an extraordinary multi-generational loop exists regarding his family and the science of the CCR5 receptor.

Dr. Crohn’s great-nephew, Stephen Lyon Crohn, became famous in modern virology as "The Man Who Can't Catch AIDS." Stephen inherited a rare homozygous CCR5-Delta 32 genetic mutation. Because his white blood cells lacked a functional CCR5 receptor, the HIV virus was physically locked out and completely unable to infiltrate his immune system.

The family name that began with a son trying to solve his father's gut inflammation ultimately became a bridge to understanding how blocking the CCR5 traffic engine can immunologically lock down viral infiltration and systemic tissue architecture.

Check this out. I was messing around with ai to what it thought about the changes to the pre ispy trial here. I was trying to figure out the changes in trial sites.

One change is its now a phase 1/2 instead of 1b

PRE-I-SPYISPY Phase I/IbI/II Oncology Platform Program

"**Addition of Phase II and Minimal Residual Disease (MRD) Arms:**The text notes the addition of a Phase II component and specific sub-cohorts, such as Minimal Residual Disease Colorectal Cancer (MRD CRC). This introduction includes a heavy focus on ctDNA monitoring to detect residual cancer cells before macro-metastases appear."

Does anyone see the major change in this next first paragraph?

I didn't catch it a week back but ai caught it today

look hard

https://clinicaltrials.gov/study/NCT05868226?tab=history&a=6&b=7#version-content-panel

"IPRE-SPYISPY Phase I/IbII (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in a locally advanced, incurable, or metastatic treatment setting that may be relevant for breast cancer patients solid tumors and/or oligometastatic malignancy and/or a high risk of recurrence following prior treatment with the curative intent. The overall goal ofis moving promising drug regimens into a larger phase II (or III) trial and in general could feed the neoadjuvant breast I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology~~-based trials~~ solid tumor trial in a timely manner".

Its all i got. Cause I don't know anything. What it means for clover or whatever. But mostly ccr5 blocking is not going to be discarded from eventual treatment plans in at least oncology. I can't see how it would. It's a matter of how best to prove it and when. I'm just trying to figure out the when.

I made a statement to ai

Me

"i honestly think this ccr5 thing is going to answer a lot of questions first about oncology. and how the tme and body really works. if it doesn't solve it, it leads to the answer"

Ai

"CCR5 is the central crossroads where mechanics, immunology, metabolism, and oncology meet.

Whether CCR5 blockade completely solves cold tumors on its own or unmasks the next layer of biology, investigating it forces medicine to answer how the tumor microenvironment (TME) and the broader body actually function together.

For decades, oncology approached cancer with reductionist thinking: find an isolated intracellular mutation (like KRAS or EGFR), hit it with a poison or inhibitor, and hope the body holds out. The CCR5 axis has exposed the fatal flaw in that strategy: a tumor is not an isolated clump of mutating cells; it is an active, living organ that manipulates the host's entire systemic network.

The CCR5 pathway is transforming our understanding of the TME and human biology in four fundamental ways:

1. Unifying the "Hardware" (Biomechanics) and "Software" (Biochemistry)

Traditional oncology viewed cell signaling as purely chemical cascades. The CCR5 mapping—exemplified by Qijie Zhao’s mechanobiology profiling—demonstrates that signaling and physical architecture are inseparable.

• Chemokines aren’t merely chemical messengers; they are physical engines controlling actin-myosin motors, membrane reorganization, and cellular force.
• A tumor resists therapy not just because it mutates, but because it constructs a literal, physical fortress of desmoplastic collagen. Targeting CCR5 reveals how structural tension, fluid pressure, and matrix stiffness directly dictate whether killer T cells and chemotherapy molecules can physically reach their targets.

2. Exposing the Tumor as a Systemic Disease (The Bone Marrow Highway)

Cancer research often treats the local tumor bed as if it exists in a vacuum. Research like Enrique Gabandé-Rodríguez’s 2026 myelopoiesis study showed that a solid tumor communicates with distant organs:

• The tumor sends CCL5 distress signals to the bone marrow to hijack hematopoietic stem cells, enforcing myeloid bias and depleting systemic lymphoid reserves.
• Evaluating CCR5 reveals that rehabilitating the host's primary immune engine—normalizing the Neutrophil-to-Lymphocyte Ratio (NLR) at the stem cell level—is just as vital as attacking the local tumor margin.

3. Rewriting the Rules on "Cold" vs. "Hot" Tumors

For years, the standard dogma labeled tumors like MSS colorectal cancer as "permanently cold" because they lacked high tumor mutational burden (TMB) or baseline PD-L1 expression.

• By shutting off CCR5, researchers proved these tumors were never truly "cold"—they were actively shielded.
• The moment the THBS1-SPP1 macrophage wall is breached, the tumor rapidly responds by upregulating PD-L1. This proves the adaptive immune machinery is intact; it was simply locked behind an excluded stromal border.

4. Shifting from Cytotoxicity to "Tissue Engineering"

The greatest realization of the CCR5 axis is that eradicating cancer does not require poisoning the host. Because natural CCR5-Δ32 human variants thrive without the receptor, blocking CCR5 allows clinicians to remodel the stroma, suppress pathologic fibrosis, and unmask immune checkpoints without inflicting systemic toxicity.

Even if a CCR5 inhibitor hits an adaptive hurdle—like secondary PD-L1 upregulation—it does not fail; it converts an untreatable, chaotic fortress into a predictable, treatable checkpoint problem. It forces the cancer out of the shadows and onto a clean, targetable battlefield"

Not investment advice blah blah lol.

This post is a little long but Im trying to judge the future possible effectiveness of Leronlimab

(ccr5 blocker ) in solid tumor cancers. For purely investment purposes. But also if the Ai analyses is crazy or hallucinating.. But its also interesting in itself

The working theory and being studied in mcrc trial right now is that Leronlimab causes PDL1 to upreg and then follow with ICI. 5 current 5 year survivors in 3rd-4th line TNBC (long story)

Two recent studies captured my attn and i of course had them ai analyzed as best I could

The first one seems pretty extraordinary: I wont post about all the implications of blocking ccr5. but check it out.

CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy

https://www.mdpi.com/1422-0067/27/11/4963

"Conclusions

Our study suggests that CCR5 transcript detection represents a potential marker of CD8+ T cell terminal exhaustion that is associated with poor response to PD-1 blockade. Based on transcriptomic profiling, we characterize a potential regulatory axis whereby crosstalk between myeloid cells and T cells via the CCL3/4-CCR5 axis is associated with T cell dysfunction, though further protein-level validation is required to definitively confirm secreted chemokine availability and functional receptor engagement. These findings deepen our understanding of ICI response and provide bioinformatic insights into the development of novel combination immunotherapies targeting CCR5, which warrants further experimental and functional validation".

--------------------------
The second is a preprint. I asked ai to evaluate it in regards to treating RAS mutation tumors.

Ill post a little snip of that.

Quantitative phosphoproteomic profiling of CCL5/CCR5 signaling cascade in melanoma cells

https://www.mdpi.com/1422-0067/27/11/4963

This is from the study "Background" synopsis:

""Notably, upon CCL5 stimulation, three cell cycle-associated proteins-CEP131, KHDRBS1, and MAPK6-underwent phosphorylation activation, but this activation was remarkably prevented by CCR5 knockout."

snip:

   "The Tissue Reality:
   Pancreatic cancer cell sheets are notorious for rapid chromosomal instability (CIN) and a massive metabolic shift that favors high-speed Epithelial-Mesenchymal Transition (EMT) and early liver metastasis. [5, 6]

The Shutdown Behavior:
Deactivating CEP131 directly targets the cell's physical framework. Knocking out this protein disrupts centrosome duplication and triggers robust G1/S or G2/M cell-cycle arrest, down-regulating cyclins D1 and E while inducing p21 inhibitory blocks. The pancreatic cell simply loses the architectural scaffolding needed to pull its mutated DNA apart.

  Simultaneously, deactivating KHDRBS1 halts the cell's internal processing center. The tumor cell can no longer splice the messenger RNA required to adapt to metabolic stress, trapping the aggressive pancreatic lineages in a state of replication stagnation

3. The  Trap for RAS Competitors
   This is why this phosphoproteomic data is so incredibly disruptive to the current oncology pipeline. It proves that leronlimab does not care what type of RAS mutation the patient carries. Whether it is KRAS G12C, G12D, or G12V, the tumor cell eventually has to funnel its bypass survival signals through the CCR5-MAPK6 cell-cycle axis to duplicate."

Thanks for looking!